MLICM
DNLI icon

Metropolitan Life Insurance Company (MetLife)’s Denali Therapeutics DNLI Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,471
Closed -$133K – 605
2024
Q1 		$133K Sell
6,471
-335
-5% -$6.3K 0.01% 904
2023
Q4 		$146K Hold
6,806
– – 0.01% 890
2023
Q3 		$140K Buy
6,806
+354
+5% +$8.98K 0.01% 851
2023
Q2 		$190K Buy
6,452
+415
+7% +$11.7K 0.01% 694
2023
Q1 		$139K Sell
6,037
-688
-10% -$18.9K 0.01% 831
2022
Q4 		$187K Buy
6,725
+780
+13% +$23.2K 0.01% 745
2022
Q3 		$182K Hold
5,945
– – 0.01% 708
2022
Q2 		$175K Buy
5,945
+366
+7% +$9.59K 0.01% 757
2022
Q1 		$179K Sell
5,579
-18,510
-77% -$637K 0.01% 871
2021
Q4 		$1.07M Hold
24,089
– – 0.01% 905
2021
Q3 		$1.22M Sell
24,089
-708
-3% -$39.9K 0.02% 818
2021
Q2 		$1.95M Buy
24,797
+7,680
+45% +$475K 0.03% 536
2021
Q1 		$977K Sell
17,117
-737
-4% -$49.3K 0.01% 939
2020
Q4 		$1.5M Hold
17,854
– – 0.02% 624
2020
Q3 		$640K Sell
17,854
-1,558
-8% -$46.9K 0.01% 1038
2020
Q2 		$469K Buy
19,412
+3,727
+24% +$87.6K 0.01% 1255
2020
Q1 		$275K Buy
15,685
+536
+4% +$11.2K 0.01% 1399
2019
Q4 		$264K Hold
15,149
– – ﹤0.01% 1730
2019
Q3 		$232K Hold
15,149
– – ﹤0.01% 1778
2019
Q2 		$314K Hold
15,149
– – 0.01% 1590
2019
Q1 		$352K Hold
15,149
– – 0.01% 1523
2018
Q4 		$313K Hold
15,149
– – 0.01% 1527
2018
Q3 		$329K Buy
+15,149
New +$251K 0.01% 1661
2018
Q2 		– Sell
-8,769
Closed -$173K – 2466
2018
Q1 		$173K Buy
+8,769
New +$180K ﹤0.01% 1978

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s DNLI Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Denali Therapeutics (DNLI) in Q2 2024, closing a stake of 6,471 shares — an estimated $133K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in DNLI in Q1 2018 and held it in 24 quarters. The position peaked at $1.95M in Q2 2021. 203 funds tracked by Wall St. Rank hold DNLI as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Denali Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 6,471 Denali Therapeutics shares in Q2 2024, an estimated $133K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Denali Therapeutics in Q1 2018 and held it in 24 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Denali Therapeutics position peaked at $1.95M in Q2 2021.
  • 203 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.